The US is currently experiencing a shortage of 15 cancer drugs as a result of manufacturing and supply chain issues. Three of these drugs – cisplatin, carboplatin and methotrexate – have been staples of cancer treatment for decades, but their supply in the US has nearly halved in the past year.
To help alleviate the shortages of carboplatin and cisplatin, the FDA has been working closely with manufacturers to identify opportunities to increase manufacturing capacity and bring companies that had stopped producing those drugs back to the US market.
